Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

MEDP US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

MEDP US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Medpace Holdings, Inc.(MEDP US)

$653.94-2.900.44%Ext:$654.43+0.490.07%(Market Closed · 00:55:24 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Medpace Holdings, Inc.(MEDP US)

$653.94-2.900.44%Ext:$654.43+0.490.07%(Market Closed · 00:55:24 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Medpace Holdings, Inc. — Company Profile

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Sector
Industrials
Industry
Professional Services
Exchange
UQ
CEO
August James Troendle
Headquarters
Cincinnati, OH, US
IPO Date
Aug 11, 2016
Employees
6,500
Website
www.medpace.com

Key Metrics

Price
$599.47
Market Cap
$16.73B
Revenue (TTM)
$706.60M
Net Income (TTM)
$123.87M
EPS (TTM)
4.35
P/E (TTM)
36.34
P/B (TTM)
27.97
Dividend Yield
0.00%
ROE (TTM)
20.70%
ROA (TTM)
5.82%
Operating Margin
20.03%
Beta
0.67

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Website
www.medpace.com
Location
Cincinnati, OH, US
Phone513 579 9911
Employees6,500
CEOAugust James Troendle
Sector
Industrials
Industry
Professional Services
IPO DateAug 11, 2016

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(922)

Expand
  • SC 13GMedpace Holdings, Inc.13 Nov
  • Form 4EWALD STEPHEN P2 Nov
  • Form 144EWALD STEPHEN P29 Oct
  • Form 4BURWIG SUSAN E28 Oct
  • Form 144BURWIG SUSAN E27 Oct
  • Form 144BURWIG SUSAN E26 Oct
  • Form 4BURWIG SUSAN E23 Oct
  • 10-QQ3ended 30 Sept 202622 Oct
  • 8-KResults of Operations and Financial Condition21 Oct
  • Form 4BURWIG SUSAN E14 Oct
  • Form 4BURWIG SUSAN E9 Oct
  • Form 4McCarthy Cornelius P. III2 Oct
  • Form 4Kraft Robert O.2 Oct
  • Form 4Carley Brian T2 Oct
  • Form 4Troendle August J.1 Oct
  • Form 4Troendle August J.29 Sep
  • SC 13D/AMedpace Holdings, Inc.28 Sep
  • Form 4Troendle August J.25 Sep
  • Form 4Troendle August J.23 Sep
  • Form 4Troendle August J.21 Sep

News

  • Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?13 Nov
  • 3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)11 Nov
  • Medpace Holdings, Inc. $MEDP Stock Sold by CenterBook Partners LP9 Nov
  • Madison Mid Cap Fund Q3 2026 Portfolio Activity6 Nov
  • CON vs. MEDP: Which Stock Is the Better Value Option?2 Nov
  • Medpace (MEDP) is a Great Momentum Stock: Should You Buy?30 Oct
  • Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?29 Oct
  • Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"26 Oct
  • All You Need to Know About Medpace (MEDP) Rating Upgrade to Buy26 Oct
  • Here's Why Medpace (MEDP) is a Strong Growth Stock26 Oct
  • Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate25 Oct
  • Medpace: 3 Key Takeaways for Long-Term Investors22 Oct
  • Medpace Holdings, Inc. (MEDP) Q3 2026 Earnings Call Transcript22 Oct
  • Medpace Q3 Earnings Call Highlights22 Oct
  • Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates21 Oct
  • A Look at Medpace Holdings Inc (MEDP) After 6.4% Gain -- GF Value $539.19 vs Price $662.4821 Oct
  • Medpace Slips Despite Third-Quarter Beat, Solid Earnings Outlook21 Oct
  • Medpace Holdings, Inc. Reports Third Quarter 2026 Results21 Oct
  • CON vs. MEDP: Which Stock Should Value Investors Buy Now?14 Oct
  • Medpace (MEDP) Dips More Than Broader Market: What You Should Know13 Oct

Mentions in Filings

  • … hnology commercialization, as well as his public company Board experience. He currently serves on the board of Magnera Corporation (NYSE: MAGN) and previously served on the boards of Nokia Corporation (NYSE: NOK) and <strong>Medpace Holdings</strong> (Nasdaq: MEDP). As Chairman, Mr. Brown will lead the Board’s oversight of the strategic actions announced in the company’s August 19 Board letter, including reductions in parent-level spending, Refinity’s funding tra …
    Innventure, Inc.Medpace Holdings, Inc.·EX-99.1 - 8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q3 26·31 Aug
  • #\*Masimo Corp. 9,064 1,244,759 \*MaxCyte, Inc. 10,028 9,093 McKesson Corp. 16,482 13,700,003 \*Medpace Holdings, Inc. 5,073 2,954,921 Medtronic PLC 169,186 17,419,391 Merck & Co., Inc. 426,648 47,046,475 \*Merit Medical Systems, Inc. 10,322 837,011 Mesa Laboratories, Inc. 1,004 79,075 \*Mettler-Toledo International, Inc. 3,523 4,837,924 \*MiMedx Group, Inc. 23,901 122,134 \*Mineralys Therapeutics, …
    Dimensional ETF TrustMedpace Holdings, Inc.·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … apeutics, Inc. \* | | 0.07% | | 146 | | 8.17 | | 1,193 | | JNJ | Johnson & Johnson | | 1.00% | | 64 | | 282.11 | | 18,055 | | LFST | LifeStance Health Group, Inc. \* | | 0.07% | | 82 | | 14.60 | | 1,197 | | MEDP | <strong>Medpace Holdings, Inc.</strong> \* | | 0.15% | | 4 | | 672.93 | | 2,692 | | MDT | Medtronic Plc † | | 0.27% | | 47 | | 102.79 | | 4,831 | | MMSI | Merit Medical Systems, Inc. \* | | 0.07% | | 14 | | 88.42 | | 1,238 | | NBIX | Neurocrine Bioscien …
    FT 13365Medpace Holdings, Inc.·487 - Form 487 - FORM S-6 TO EFFECTIVE AMENDMENT·Q4 26·10 Nov
  • … \* | | 2.51 | % | | 33 | | 128.01 | | 4,224 | | JAZZ | Jazz Pharmaceuticals Plc †\* | | 2.45 | % | | 20 | | 205.70 | | 4,114 | | KRYS | Krystal Biotech, Inc. \* | | 2.42 | % | | 13 | | 313.66 | | 4,078 | | MEDP | <strong>Medpace Holdings, Inc.</strong> \* | | 2.41 | % | | 6 | | 676.77 | | 4,061 | | NBIX | Neurocrine Biosciences, Inc. \* | | 2.52 | % | | 29 | | 145.87 | | 4,230 | | UTHR | United Therapeutics Corporation \* | | 2.47 | % | | 7 | | 592.84 | | 4,150 …
    FT 13297Medpace Holdings, Inc.·487 - Form 487 - FORM S-6 TO EFFECTIVE AMENDMENT·Q4 26·27 Oct
  • … iotech, Inc. \* | | 0.19% | | 9 | | 332.07 | | 2,989 | | LFST | LifeStance Health Group, Inc. \* | | 0.10% | | 124 | | 12.48 | | 1,547 | | MCK | McKesson Corporation | | 0.49% | | 8 | | 955.76 | | 7,646 | | MEDP | <strong>Medpace Holdings, Inc.</strong> \* | | 0.20% | | 5 | | 620.05 | | 3,100 | | MDT | Medtronic Plc † | | 0.40% | | 67 | | 91.93 | | 6,159 | | MMSI | Merit Medical Systems, Inc. \* | | 0.10% | | 17 | | 89.75 | | 1,526 | | NTRA | Natera, Inc. \* | | …
    FT 13273Medpace Holdings, Inc.·S-6/A - AMENDMENT TO REGISTRATION STATEMENT·Q4 26·13 Oct
  • … Biotech, Inc. \* | | 0.14% | | 7 | | 332.07 | | 2,324 | | LFST | LifeStance Health Group, Inc. \* | | 0.07% | | 89 | | 12.48 | | 1,111 | | MCK | McKesson Corporation | | 0.34% | | 6 | | 955.76 | | 5,735 | | MEDP | <strong>Medpace Holdings, Inc.</strong> \* | | 0.15% | | 4 | | 620.05 | | 2,480 | | MDT | Medtronic Plc † | | 0.26% | | 48 | | 91.93 | | 4,413 | | MMSI | Merit Medical Systems, Inc. \* | | 0.06% | | 12 | | 89.75 | | 1,077 | | NTRA | Natera, Inc. \* | | …
    FT 13272Medpace Holdings, Inc.·S-6/A - AMENDMENT TO REGISTRATION STATEMENT·Q4 26·13 Oct

Key Stats

Trading

Px/Chg 1D$599.47 / +0.23%
Avg Volume361.34K
Beta0.67
Mkt Cap16.73B
FD Mkt Cap16.51B

Float

Shrs Out/Float27.91M / 22.50M
Short Float0.09%
Days to Cover5.86
Stock Repurchased$0.00

Current Valuation

EV16.20B
EV/EBITDA27.65
EV/Sales6.05
P/B27.97
P/S6.25
FCF Yield0.87%
ROE20.70%
ROA5.82%
Current Ratio0.85

Estimates

P/E36.34
Est P/E0.00
Est EPS3.92
Est PEG0.00

Valuation

Metric5Yr AvgApr '23Apr '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings65.8524.7240.8722.12106.45135.08
Price / Sales11.704.156.134.2420.3023.68
Price / Book Value21.3015.7020.6810.8431.3327.97
Price / Free Cash Flow50.7817.2729.1415.6376.47115.42
ENTERPRISE VALUE METRICS
Enterprise Value11,289.66,225.611,456.18,426.414,138.316,201.8
Enterprise Value / Sales11.444.266.074.0019.9622.93
Enterprise Value / EBITDA52.2020.6831.5517.7086.23104.87
Enterprise Value / EBIT55.0322.3434.0118.8690.15109.77

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue22%1,142.41,460.01,885.82,109.12,530.2
Gross Income23.4%328.2432.4524.5656.3760.6
EBITDA26.9%219.7301.0363.2476.1570.5
EBIT28.6%198.6278.7336.8446.9542.4
Net Income25.5%181.8245.4282.8404.4451.1
EPS (Diluted)33.5%4.817.288.8812.6315.28
BALANCE SHEET
Cash & ST Inv1.9%461.328.3245.4669.4497.0
Total Assets4.4%1,659.91,352.51,656.82,100.91,975.5
Total Liabilities21%707.0966.11,097.91,275.31,516.4
Total Shareholder Equity-16.7%952.9386.4559.0825.5459.1
CASH FLOW
Net Operating Cash Flow28.3%263.3388.1433.4608.8713.2
Cap Ex2.6%-28.3-36.9-36.6-36.5-31.4
Free Cash Flow30.5%235.1351.2396.7572.3681.9

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)651.39
Basic Shares27.91
Market Cap18,181.3
Diluted Shares28.37
Fully Diluted Shares Outstanding28.37
Fully Diluted Market Cap18,481.1
+Consolidated Debt146.0
−In-the-Money Convertible Debt—
+Capital Leases146.0
+Operating Leases—
−Cash & Equivalents-705.3
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value17,622.0

Segment data

Revenue

by Products and services

  • Oncology30%
  • Metabolic29%
  • Other16%
  • Central Nervous System10%
  • Cardiology9%

Related companies

Iqvia Holdings Inc.

IQV US

Wanhua Chemical Group Co., Ltd.

600309 CG

Novozymes As/fi

NVZMY US

DSM-Firmenich AG/ADR

DSFIR NA

L Air Liquide Sa /FI

AIQUY US

EMS-Chemie Holding AG/ADR

EMSHF US

Incyte Corp

INCY US

Grace Fabric Technology Co.,Ltd.

603256 CG

Nippon Paint Holdings Co., Ltd.

NPCPF US

Covestro AG/ADR

COVTY US

Symrise AG

SYIEY US

Charles River Laboratories International, Inc.

CRL US

Medpace Holdings, Inc. — Company Profile

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Sector
Industrials
Industry
Professional Services
Exchange
UQ
CEO
August James Troendle
Headquarters
Cincinnati, OH, US
IPO Date
Aug 11, 2016
Employees
6,500
Website
www.medpace.com

Key Metrics

Price
$599.47
Market Cap
$16.73B
Revenue (TTM)
$706.60M
Net Income (TTM)
$123.87M
EPS (TTM)
4.35
P/E (TTM)
36.34
P/B (TTM)
27.97
Dividend Yield
0.00%
ROE (TTM)
20.70%
ROA (TTM)
5.82%
Operating Margin
20.03%
Beta
0.67

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Website
www.medpace.com
Location
Cincinnati, OH, US
Phone513 579 9911
Employees6,500
CEOAugust James Troendle
Sector
Industrials
Industry
Professional Services
IPO DateAug 11, 2016

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(922)

Expand
  • SC 13GMedpace Holdings, Inc.13 Nov
  • Form 4EWALD STEPHEN P2 Nov
  • Form 144EWALD STEPHEN P29 Oct
  • Form 4BURWIG SUSAN E28 Oct
  • Form 144BURWIG SUSAN E27 Oct
  • Form 144BURWIG SUSAN E26 Oct
  • Form 4BURWIG SUSAN E23 Oct
  • 10-QQ3ended 30 Sept 202622 Oct
  • 8-KResults of Operations and Financial Condition21 Oct
  • Form 4BURWIG SUSAN E14 Oct
  • Form 4BURWIG SUSAN E9 Oct
  • Form 4McCarthy Cornelius P. III2 Oct
  • Form 4Kraft Robert O.2 Oct
  • Form 4Carley Brian T2 Oct
  • Form 4Troendle August J.1 Oct
  • Form 4Troendle August J.29 Sep
  • SC 13D/AMedpace Holdings, Inc.28 Sep
  • Form 4Troendle August J.25 Sep
  • Form 4Troendle August J.23 Sep
  • Form 4Troendle August J.21 Sep

News

  • Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?13 Nov
  • 3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)11 Nov
  • Medpace Holdings, Inc. $MEDP Stock Sold by CenterBook Partners LP9 Nov
  • Madison Mid Cap Fund Q3 2026 Portfolio Activity6 Nov
  • CON vs. MEDP: Which Stock Is the Better Value Option?2 Nov
  • Medpace (MEDP) is a Great Momentum Stock: Should You Buy?30 Oct
  • Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?29 Oct
  • Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"26 Oct
  • All You Need to Know About Medpace (MEDP) Rating Upgrade to Buy26 Oct
  • Here's Why Medpace (MEDP) is a Strong Growth Stock26 Oct
  • Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate25 Oct
  • Medpace: 3 Key Takeaways for Long-Term Investors22 Oct
  • Medpace Holdings, Inc. (MEDP) Q3 2026 Earnings Call Transcript22 Oct
  • Medpace Q3 Earnings Call Highlights22 Oct
  • Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates21 Oct
  • A Look at Medpace Holdings Inc (MEDP) After 6.4% Gain -- GF Value $539.19 vs Price $662.4821 Oct
  • Medpace Slips Despite Third-Quarter Beat, Solid Earnings Outlook21 Oct
  • Medpace Holdings, Inc. Reports Third Quarter 2026 Results21 Oct
  • CON vs. MEDP: Which Stock Should Value Investors Buy Now?14 Oct
  • Medpace (MEDP) Dips More Than Broader Market: What You Should Know13 Oct

Mentions in Filings

  • … hnology commercialization, as well as his public company Board experience. He currently serves on the board of Magnera Corporation (NYSE: MAGN) and previously served on the boards of Nokia Corporation (NYSE: NOK) and <strong>Medpace Holdings</strong> (Nasdaq: MEDP). As Chairman, Mr. Brown will lead the Board’s oversight of the strategic actions announced in the company’s August 19 Board letter, including reductions in parent-level spending, Refinity’s funding tra …
    Innventure, Inc.Medpace Holdings, Inc.·EX-99.1 - 8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q3 26·31 Aug
  • #\*Masimo Corp. 9,064 1,244,759 \*MaxCyte, Inc. 10,028 9,093 McKesson Corp. 16,482 13,700,003 \*Medpace Holdings, Inc. 5,073 2,954,921 Medtronic PLC 169,186 17,419,391 Merck & Co., Inc. 426,648 47,046,475 \*Merit Medical Systems, Inc. 10,322 837,011 Mesa Laboratories, Inc. 1,004 79,075 \*Mettler-Toledo International, Inc. 3,523 4,837,924 \*MiMedx Group, Inc. 23,901 122,134 \*Mineralys Therapeutics, …
    Dimensional ETF TrustMedpace Holdings, Inc.·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … apeutics, Inc. \* | | 0.07% | | 146 | | 8.17 | | 1,193 | | JNJ | Johnson & Johnson | | 1.00% | | 64 | | 282.11 | | 18,055 | | LFST | LifeStance Health Group, Inc. \* | | 0.07% | | 82 | | 14.60 | | 1,197 | | MEDP | <strong>Medpace Holdings, Inc.</strong> \* | | 0.15% | | 4 | | 672.93 | | 2,692 | | MDT | Medtronic Plc † | | 0.27% | | 47 | | 102.79 | | 4,831 | | MMSI | Merit Medical Systems, Inc. \* | | 0.07% | | 14 | | 88.42 | | 1,238 | | NBIX | Neurocrine Bioscien …
    FT 13365Medpace Holdings, Inc.·487 - Form 487 - FORM S-6 TO EFFECTIVE AMENDMENT·Q4 26·10 Nov
  • … \* | | 2.51 | % | | 33 | | 128.01 | | 4,224 | | JAZZ | Jazz Pharmaceuticals Plc †\* | | 2.45 | % | | 20 | | 205.70 | | 4,114 | | KRYS | Krystal Biotech, Inc. \* | | 2.42 | % | | 13 | | 313.66 | | 4,078 | | MEDP | <strong>Medpace Holdings, Inc.</strong> \* | | 2.41 | % | | 6 | | 676.77 | | 4,061 | | NBIX | Neurocrine Biosciences, Inc. \* | | 2.52 | % | | 29 | | 145.87 | | 4,230 | | UTHR | United Therapeutics Corporation \* | | 2.47 | % | | 7 | | 592.84 | | 4,150 …
    FT 13297Medpace Holdings, Inc.·487 - Form 487 - FORM S-6 TO EFFECTIVE AMENDMENT·Q4 26·27 Oct
  • … iotech, Inc. \* | | 0.19% | | 9 | | 332.07 | | 2,989 | | LFST | LifeStance Health Group, Inc. \* | | 0.10% | | 124 | | 12.48 | | 1,547 | | MCK | McKesson Corporation | | 0.49% | | 8 | | 955.76 | | 7,646 | | MEDP | <strong>Medpace Holdings, Inc.</strong> \* | | 0.20% | | 5 | | 620.05 | | 3,100 | | MDT | Medtronic Plc † | | 0.40% | | 67 | | 91.93 | | 6,159 | | MMSI | Merit Medical Systems, Inc. \* | | 0.10% | | 17 | | 89.75 | | 1,526 | | NTRA | Natera, Inc. \* | | …
    FT 13273Medpace Holdings, Inc.·S-6/A - AMENDMENT TO REGISTRATION STATEMENT·Q4 26·13 Oct
  • … Biotech, Inc. \* | | 0.14% | | 7 | | 332.07 | | 2,324 | | LFST | LifeStance Health Group, Inc. \* | | 0.07% | | 89 | | 12.48 | | 1,111 | | MCK | McKesson Corporation | | 0.34% | | 6 | | 955.76 | | 5,735 | | MEDP | <strong>Medpace Holdings, Inc.</strong> \* | | 0.15% | | 4 | | 620.05 | | 2,480 | | MDT | Medtronic Plc † | | 0.26% | | 48 | | 91.93 | | 4,413 | | MMSI | Merit Medical Systems, Inc. \* | | 0.06% | | 12 | | 89.75 | | 1,077 | | NTRA | Natera, Inc. \* | | …
    FT 13272Medpace Holdings, Inc.·S-6/A - AMENDMENT TO REGISTRATION STATEMENT·Q4 26·13 Oct

Key Stats

Trading

Px/Chg 1D$599.47 / +0.23%
Avg Volume361.34K
Beta0.67
Mkt Cap16.73B
FD Mkt Cap16.51B

Float

Shrs Out/Float27.91M / 22.50M
Short Float0.09%
Days to Cover5.86
Stock Repurchased$0.00

Current Valuation

EV16.20B
EV/EBITDA27.65
EV/Sales6.05
P/B27.97
P/S6.25
FCF Yield0.87%
ROE20.70%
ROA5.82%
Current Ratio0.85

Estimates

P/E36.34
Est P/E0.00
Est EPS3.92
Est PEG0.00

Valuation

Metric5Yr AvgApr '23Apr '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings65.8524.7240.8722.12106.45135.08
Price / Sales11.704.156.134.2420.3023.68
Price / Book Value21.3015.7020.6810.8431.3327.97
Price / Free Cash Flow50.7817.2729.1415.6376.47115.42
ENTERPRISE VALUE METRICS
Enterprise Value11,289.66,225.611,456.18,426.414,138.316,201.8
Enterprise Value / Sales11.444.266.074.0019.9622.93
Enterprise Value / EBITDA52.2020.6831.5517.7086.23104.87
Enterprise Value / EBIT55.0322.3434.0118.8690.15109.77

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue22%1,142.41,460.01,885.82,109.12,530.2
Gross Income23.4%328.2432.4524.5656.3760.6
EBITDA26.9%219.7301.0363.2476.1570.5
EBIT28.6%198.6278.7336.8446.9542.4
Net Income25.5%181.8245.4282.8404.4451.1
EPS (Diluted)33.5%4.817.288.8812.6315.28
BALANCE SHEET
Cash & ST Inv1.9%461.328.3245.4669.4497.0
Total Assets4.4%1,659.91,352.51,656.82,100.91,975.5
Total Liabilities21%707.0966.11,097.91,275.31,516.4
Total Shareholder Equity-16.7%952.9386.4559.0825.5459.1
CASH FLOW
Net Operating Cash Flow28.3%263.3388.1433.4608.8713.2
Cap Ex2.6%-28.3-36.9-36.6-36.5-31.4
Free Cash Flow30.5%235.1351.2396.7572.3681.9

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)651.39
Basic Shares27.91
Market Cap18,181.3
Diluted Shares28.37
Fully Diluted Shares Outstanding28.37
Fully Diluted Market Cap18,481.1
+Consolidated Debt146.0
−In-the-Money Convertible Debt—
+Capital Leases146.0
+Operating Leases—
−Cash & Equivalents-705.3
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value17,622.0

Segment data

Revenue

by Products and services

  • Oncology30%
  • Metabolic29%
  • Other16%
  • Central Nervous System10%
  • Cardiology9%

Related companies

Iqvia Holdings Inc.

IQV US

Wanhua Chemical Group Co., Ltd.

600309 CG

Novozymes As/fi

NVZMY US

DSM-Firmenich AG/ADR

DSFIR NA

L Air Liquide Sa /FI

AIQUY US

EMS-Chemie Holding AG/ADR

EMSHF US

Incyte Corp

INCY US

Grace Fabric Technology Co.,Ltd.

603256 CG

Nippon Paint Holdings Co., Ltd.

NPCPF US

Covestro AG/ADR

COVTY US

Symrise AG

SYIEY US

Charles River Laboratories International, Inc.

CRL US